Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection
NCT ID: NCT04094467
Last Updated: 2020-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
150 participants
INTERVENTIONAL
2019-12-07
2021-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction
NCT07168837
Comparison Between Laparoscopic Ovarian Diathermy and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome.
NCT02304536
Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial
NCT02024984
Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women
NCT06486870
Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS)
NCT02305693
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
the antagonist protocol group" where they will do intra-cytoplasmic injection using classical antagonist protocol
Cetrorelix
0.25 mg subcutaneous injection daily for 6 days
control group
"agonist stop/antagonist protocol group" where they will receive mid luteal agonist in the preceding intra-cytoplasmic injection cycle before starting classical antagonist protocol
Cetrorelix
0.25 mg subcutaneous injection daily for 6 days
Leuprolide Acetate
0.1 mg subcutaneous injection daily for 12 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cetrorelix
0.25 mg subcutaneous injection daily for 6 days
Leuprolide Acetate
0.1 mg subcutaneous injection daily for 12 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Normal male semen parameters
3. Normal tubes either by hysterosalpingography \&/or laparoscopy
4. Free from other endocrine abnormalities
Exclusion Criteria
2. More than 35 years
3. Abnormal semen parameters
4. Pathological tube\& pelvic factor
5. Other endocrine disorders
20 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Mohamed Abbas
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ahmed Abbas
Assiut, Cairo Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
ahmed abbas
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PCOS-ICSI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.